Predicting severe acute GvHD (aGvHD) after allogeneic hematopoietic stem cell transplantation (HSCT) is challenging but critical. Mild aGvHD may have a favorable impact on relapse, whereas severe aGvHD is associated with poor outcomes. The aim of this study was to evaluate whether elevated eosinophil count in the bone marrow (BM) at 1 month after HSCT is associated with a high incidence of new and severe aGvHD. We enrolled 101 consecutive patients; median age was 50 years, and 50.5% patients were male. The median eosinophil concentration in BM at 1 month after HSCT was 1.1% (quartile 0.4-2.2%). The adjusted hazards ratio at 95% confidence interval for severe aGvHD was 1.26 (1.12-1.42, P o 0.001), per 1% increase in eosinophil concentration, and 3.76 (1.41-10.05, P = 0.008) for the high-risk group at a cutoff value of 4.0%. In addition, the predictive accuracy described by area under the curve of receiver operating characteristics, increased from 0.784 to 0.866 (P = 0.033) with the increasing concentration of eosinophils. In conclusion, elevated concentration of eosinophils in BM was associated with high incidence and predictive accuracy of severe aGvHD. BM eosinophil concentration can be one of the key markers to predict aGvHD.
INTRODUCTION
Acute GvHD (aGvHD) is a common and significant complication of allogeneic hematopoietic stem cell transplantation (HSCT). It occurs when T lymphocytes of donor origin recognize the recipient cells as foreign and initiate immune reactions. The skin, gastrointestinal tract and liver are principally involved, and the severity of aGvHD is determined using the Glucksberg grade system, 1,2 which calculates a score based on the degree of involvement of these organs. Although it is known that severe aGvHD defined as grades 2-4, is one of the leading causes of transplant-related mortality, recent evidence also suggests that aGvHD can have a twofold impact. It may have a favorable impact on relapse after HSCT, which is known as the graft-versusleukemia effect. [3] [4] [5] Hence, predicting severe aGvHD is clinically essential. The aGvHD prophylaxis regimen can be tailored for improved outcomes, based on the predicted severity of aGvHD. [6] [7] [8] Prediction of severe aGvHD using serum biomarkers is under rigorous investigation by researchers. Suppression of tumorigenicity 2 (ST2) cell counts using flow cytometry or microRNA are reported to be significant parameters for the prediction of severe aGvHD. [9] [10] [11] On the other hand, several studies evaluating histological findings of aGvHD, demonstrated infiltration of eosinophils in the involved organs, indicating an association between eosinophils and aGvHD. [12] [13] [14] [15] [16] [17] [18] Eosinophil infiltration in the target tissue after HSCT is acquired from donor cells, and their production in the bone marrow (BM) is stimulated by several physiologically active substances including interleukin-5, which are produced due to the allo-reactive immune response. Basara et al. 19 reported the association between elevated eosinophils in BM and grades 3-4 aGvHD after HSCT, in their preliminary correspondence. The study included patients presenting with aGvHD on BM examination; however, no multivariate analysis was performed despite the presence of many confounding factors such as HLA mismatch. Hence, we evaluated whether eosinophil concentration in BM at 1-month after HSCT is associated with subsequent development of severe aGvHD in patients with HSCT, who had no aGvHD at the time of BM examination.
PATIENTS AND METHODS

Study patients
Of the 169 consecutive patients who underwent allogeneic HSCT at Kobe City Hospital Organization, Kobe City Medical Center General Hospital, or Foundation for Biomedical Research and Innovation between October 2010 and December 2015, 101 patients who underwent microscopic examination of BM at 1-month after HSCT, and were free of aGvHD, were enrolled in the present study ( Figure 1 conditioning was the others. [20] [21] [22] All patients received a calcineurin inhibitor-based aGvHD prophylaxis. A combined regimen of cyclosporine A and short-term methotrexate was administered to patients who received BM stem cell transplantation from a related donor. A regimen of tacrolimus (Tac) and mycophenolate or Tac and short-term methotrexate was administered to patients who received cord blood stem cell transplantation, and a regimen of Tac and short-term methotrexate was prescribed for other patients. Post-transplant cyclophosphamide was administrated to patients who received HLA-haploidentical stem cell transplantation. Anti-thymoglobulin was administered to patients with aplastic anemia and to some patients who received HLA-mismatch stem cell transplantation. Conditioning regimens and aGvHD prophylaxis tended to follow the principal, but was finally determined by the respective attending physician. BM stem cell units and peripheral blood (PB) stem cell units were sourced from the Japan Marrow Donor Program or related donors, and cord blood stem cell units were sourced from the Japanese Cord Blood Bank Network.
Microscopic examinations of BM
Microscopic examinations of BM were performed to determine the concentration of eosinophils, and PB counts were performed for use as reference. PB smear was obtained on the same day as examination of BM (±1day). BM aspirate and PB smears were stained with May-Grünwald Giemsa stain and were each reviewed by a faculty hematologist or medical technologist, at a magnification of × 60. A differential count of 500 cells was carried out for each BM smear and eosinophil concentrations were recorded, and a differential count of 200 cells was done for cases with low cellularity. A 100 cell differential count was also carried out for each PB smear, and eosinophil concentrations were recorded. To minimize intraand inter-observer variations, 30 randomly selected cases were reviewed Abbreviations: BM = bone marrow; HSCT = hematopoietic stem cell transplantation; MAC = myeloablative conditioning regimen; NA = not applicable; PB = peripheral blood. Low risk group was defined as patients with eosinophil concentration in BM ⩽ 4%, and high-risk group had concentration 44%. Continuous variables were summarized as medians and interquartile range (quartiles 1-3), and categorical variables were summarized as counts and percentages. Corticosteroid doses are expressed as the converted amount of methylprednisolone as calculated by multiplying the dose of prednisolone by 0.8.
by 2 independent hematologists or medical technologists, who were blinded to patient information.
Statistical analysis
The primary endpoint was severe aGvHD, defined as grades 2-4 aGvHD within 70 days of the microscopic examinations of BM (100 days after the HSCT). Grades 2-4 aGvHD was defined as per the Glucksberg grade system. 1,2 Competing risks for severe aGvHD were defined as relapse and death from all cause. All data were retrospectively obtained from patient records. Continuous variables were summarized as medians and interquartile ranges (quartiles 1-3), and categorical variables were summarized as counts and percentages. Corticosteroid doses were summarized only for patients who received corticosteroids at the time of BM examination; they are expressed as the converted amount of methylprednisolone as calculated by multiplying the dose of prednisolone by 0.8. Intra-and inter-observer variations in eosinophil counts of BM were assessed using intraclass correlation coefficient on a randomly selected data of 30 cases. To evaluate the impact of BM and PB eosinophil concentration on the primary endpoint, we employed multivariable Fine and Gray competing risks regression model, using eosinophil concentration as a continuous variable. Adjusted covariates were as follows; age, sex, donor source, unrelated donor, HLA mismatch and corticosteroid doses at the time of BM examination. To arrive at a simple risk stratification, we divided the patients into two risk groups (high versus low risk groups) using the survival classification and regression tree analysis. The classification and regression tree method is an empirical, statistical technique based on recursive partitioning analysis and is useful to arrive at clinical decisions and risk stratification models. 23 Both patient risk groups were treated as a categorical variable, and the impact on primary endpoint was evaluated using the multivariable Fine and Gray competing risks regression model. Patients and disease characteristics were compared using the Mann-Whitney U test for continuous variables and χ 2 test for categorical variables between the 2 groups. Cumulative incidence of severe aGvHD was also estimated using the competing risk model with 95% confidence interval (CI). The prediction accuracy of eosinophil count for the development of severe aGvHD was assessed comparing the area under the curve of receiver operating characteristics (ROC) using the logistic regression model. We first created a standard model for prediction of severe aGvHD based on patient background and previously reported risk factors for aGvHD. The standard model was adjusted for all clinical parameters other than eosinophil concentration, as seen in Table 1 . We then evaluated whether the incorporation of BM eosinophil concentration in the standard model would improve the predictive accuracy of severe aGvHD. Statistical significance was set as Po0.05. All statistical analyses were performed using R software packages (version 3.1.1; R Development Core Team).
RESULTS
Patients characteristics
The characteristics of 101 patients enrolled and analyzed in the present study (Figure 1 ) are described in Table 1 . There were no missing data in this study. Median age was 50 years, and 51 (50.5%) patients were male. 52 (51.5%) patients received BM transplantation, 18 (17.8%) received PB transplantation and 31 (30.7%) received cord blood transplantation. In the study population, 71 (70.3%) patients received the transplant from unrelated donors and 48 (47.5%) patients received it from an HLA-mismatched donor. At the time of BM examination, 7 patients received corticosteroid therapy at a dose of 20 mg/day.
15-27
The median eosinophil concentration in BM was 1.1% (quartile 0.4-2.2%) and that in PB was 0.5% (0.0-2.0%). The intraclass correlation coefficient of eosinophil concentration in BM was 0.908 (95% CI 0.818-0.955, P o 0.001) and 0.911 (95% CI 0.816-0.957, P o0.001) for intra-and inter-observer variations, respectively. The survival classification and regression tree analysis revealed that the cutoff eosinophil concentration to predict the incidence of severe aGvHD was 4.0% in BM and no cutoff point could be determined in PB. Thus, we defined patients with eosinophil concentration in BM ⩽ 4.0% as low risk group, and patients with eosinophil concentration in BM 44.0% as high-risk group. There were no significant differences in patient characteristics between the 2 groups, except for the source of stem cells and the percentage of unrelated donors ( Table 1) .
Development of aGvHD There were 18 cases of grades 2-4 severe aGvHD, 12 cases of relapse and 5 treatment related deaths in this study ( Table 2 ). The cumulative incidence of severe aGvHD at 70 days after BM Figure 3) . A representative case is shown in Figure 4 .
DISCUSSION
In the present study, we demonstrated that elevated concentration of eosinophils in the BM is associated with high incidence of severe aGvHD after HSCT and determining eosinophil concentration during BM microscopic examination significantly improved the predictive accuracy of future severe aGvHD. Since little evidence is available on the association between eosinophil concentration in BM and incidence of aGvHD, our results provide physicians with additional information on the subject. We hope eosinophil counts in BM after HSCT would be useful for predicting severe aGvHD, and for designing risk-adapted tailored immunosuppression intensity in the future. The possible association between eosinophils and aGvHD has been previously reported. Infiltration of eosinophils in the skin, gastrointestinal tract and liver in patients with aGvHD is often observed and may be harmful.
12-14, 18 Basara et al. 19 reported that an elevated concentration of eosinophils in BM was associated with grades 3-4 aGvHD after HSCT in their preliminary findings. On the other hand, there are some reports about an association between elevated concentration of eosinophils in PB and aGvHD; however, the association is still controversial, possibly due to the influence of corticosteroid therapy. [15] [16] [17] 24, 25 As mentioned in previous report from Basara et al., our results also showed that increased concentration of eosinophils in BM was associated with Abbreviations: aGvHD = acute graft versus host disease; BM = bone marrow; CI = confidence interval; HR = hazard ratio. Multivariate analysis was adjusted for age, sex, donor source, unrelated donor, HLA mismatch and corticosteroid dose at the time of BM examination.
Delong P =0. development of severe aGvHD in the future, even after adjustments of covariates including corticosteroid doses; however, no association was found between eosinophil concentration in PB and aGvHD. The results suggest that an elevated concentration of eosinophils in BM might represent an initial immune reaction leading to severe aGvHD. As the corticosteroid is used for treatment or prophylaxis of aGvHD, the impact of steroid therapy on eosinophil count in the BM is another area of interest. The role of eosinophils in aGvHD is still unclear. The release of eosinophil peroxidase into the extracellular space has cytopathogenic effects on the intestinal epithelium in celiac and Crohn's disease. 26 In organ transplant, the correlation between infiltration and activation of eosinophils and allograft rejection has been previously reported. 27, 28 Similar outcomes were observed for aGvHD. 13 In addition, some reports revealed the correlation between aGvHD and interleukin-5, which suggests a correlation between eosinophils and aGvHD, because interleukin-5 stimulates production of eosinophils in BM and inhibits apoptosis. [29] [30] [31] Eosinophils may proliferate on activation by interleukin-5 and other cytokines produced by T cells, following which they infiltrate into the target tissue and cause injury to these tissues by releasing peroxidase.
Prediction of severe aGvHD is challenging and critical after HSCT. One of the most important markers for the prediction of aGvHD is ST2, which acts as a decoy receptor for interleukin-33, limiting its access to type 2T helper cell and promoting the type 1T helper cell phenotype. Ponce et al. 9 reported that the ST2 levels at 28 days after cord blood stem cell transplantation appeared to predict the development of grades 3-4 aGvHD. The adjusted HR (95% CI) of ST2 high group compared to low group was 2.62 (1.06-6.45, P = 0.036). Another study observed that the 4 plasma microRNA biomarker panel, which includes inflammation, tissue damage, regulation of cell proliferation and in tissue repair, could predict further progress of grades 2-4 aGvHD. 11 The area under the curve (95% CI) for the combined microRNA biomarker panel was 0.85 (0.76-0.93, P o 0.001). 11 In the present study, we showed that elevated concentration of eosinophils in BM at 28 days after HSCT predicted the progression of grades 2-4 aGvHD. The evaluation of eosinophils in BM is less expensive and more accessible, compared to previously reported indices such as ST2 or microRNA. However, BM aspiration is more invasive and cannot be performed frequently. However, the evaluation of eosinophils in BM can be performed in patients with indices predictive of severe aGvHD, and may be clinically useful because of its cost and accessibility.
We described that an elevated concentration of eosinophils in BM may be a marker for prediction of severe aGvHD. As the previously reported markers such as ST2 and microRNA are not known to be associated with eosinophils, a combined use of concentration of eosinophils in BM and other predictive markers may have the potential to improve predictive value. The optimal timing to perform microscopic examinations of BM is yet to be determined. We performed microscopic examinations of BM at 28 days after allogeneic HSCT. Considering that almost one-third of patients (49 patients) had developed aGvHD before the microscopic examinations of BM, determination of the optimal timing of the BM evaluation could be a future objective. Early prediction of the risk of mild or severe aGvHD can lead to preemptive interventions such as administering higher therapeutic calcineurin inhibitor levels to prevent severe aGvHD or tapering immunosuppressive agents rapidly to produce stronger graft versus leukemia effect, which may improve the prognosis of patients undergoing HSCT.
There are some limitations in this study. First, this is a retrospective single institution study. Second, we used morphologic analysis to detect the presence of eosinophils. It is still unknown which phenotype of eosinophils is associated with aGvHD, although activated phenotypes of eosinophils in the tissues has been reported to be associated with severe aGvHD. 13 Finally, the optimal time to perform microscopic examinations of BM is yet to be determined. Further studies are necessary to find these answers.
In conclusion, an elevated concentration of eosinophils in BM was associated with high incidence of severe aGvHD and improved the predictive accuracy of severe aGvHD after HSCT. Eosinophil counts in BM are an important marker to predict aGvHD, and the optimal timing of microscopic examinations of BM and phenotype of eosinophils are subjects of further study.
